This is the authors' abstract. We don't add key points for this paper.
Background/Aim: This study aimed at evaluating the potential benefit of automatic non-coplanar volumetric arc therapy (VMAT) (hyperarc, HA) technique in treating glioblastoma multiforme (GBM). Patients and Methods: Twenty-seven patients with GBM who received coplanar VMAT (C-VMAT) were selected in this study. HA and non-coplanar VMAT (NC-VMAT) plans were generated with the same prescriptions and constraints. The Target coverage, organs at risk (OARs) dose, and dosimetric indexes were compared among three plans. Results: The HA plan demonstrated a reduction in dose to normal tissues while maintaining target coverage, compared to C-VMAT and NC-VMAT. Additionally, HA plans demonstrated higher coverage of the GTV and PTV₆₀ as well as improved CI from PTV₆₀ and PTV₄₆ compared to the other plans. Regarding the dose gradient, HA plans showed a greater dose fall-off, resulting in reduced high-dose and intermediate-dose spillage at PTV₄₆. The HA also demonstrated a tighter gradient radius at PTV₆₀ and PTV₄₆. The HA plan requires fewer MUs than both C-VMAT and NC-VMAT. Conclusion: The HA plan had better dosimetric results compared to C-VMAT and NC-VMAT. The HA with automatic planning module and auto-delivery treatment also provided high-quality planning and delivery efficacy. These advantages suggest that HA could potentially escalate tumor doses while minimizing toxicity, thereby improving outcomes in GBM patients.
No takes yet. Share an insight, caveat, or question.
HONG et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: